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Abstract:  The  lysophospholipids  sphingosine  1-phosphate  (S1P)  and  lysophosphatidic 
acid (LPA) act via G-protein coupled receptors S1P1–5 and LPA1–3 respectively, and are 
implicated in allergy. Eosinophils accumulate at innervating cholinergic nerves in asthma 
and  adhere  to  nerve  cells  via  intercellular  adhesion  molecule-1  (ICAM-1).  IMR-32 
neuroblastoma cells were used as an in vitro cholinergic nerve cell model. The Gi coupled 
receptors  S1P1,  S1P3,  LPA1,  LPA2  and  LPA3  were  expressed  on  IMR-32  cells.  Both  
S1P and LPA induced ERK phosphorylation and ERK- and Gi-dependent up-regulation  
of  ICAM-1  expression,  with  differing  time  courses.  LPA  also  induced  ERK-  and  
Gi-dependent  up-regulation  of  the  eosinophil  chemoattractant,  CCL-26.  The  eosinophil 
granule  protein  eosinophil  peroxidase  (EPO)  induced  ERK-dependent  up-regulation  of 
transcription of S1P1, LPA1, LPA2 and LPA3, providing the situation whereby eosinophil 
granule proteins may enhance S1P- and/or LPA- induced eosinophil accumulation at nerve 
cells in allergic conditions. 
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1. Introduction  
In animal models of asthma, and in many asthma patients, antigen inhalation results in inhibition of 
muscarinic  M2  receptors  on  parasympathetic  nerves,  leading  to  acetylcholine  release  and  hence 
mucous secretion and contraction of bronchial smooth muscle [1]. 
Eosinophilia is a hallmark of allergic diseases such as asthma and allergic rhinitis [2]. Eosinophils 
accumulate  at  innervating  cholinergic  nerves  in  human  and  animal  models  of  allergic  conditions, 
contributing to nerve hyperresponsiveness due to eosinophil major basic protein (MBP)-mediated M2 
antagonism  [3,4].  Eosinophil  accumulation  at  airway  nerves  is  mediated  by  eosinophil  CCR3  
receptors [5]. We have employed the neuroblastoma cell line IMR-32 as a useful in vitro model of 
cholinergic nerve cell function. Differentiated IMR-32 cells express neuronal muscarinic M2 receptors 
and  release  acetylcholine  in  response  to  eosinophil  adhesion  via  nerve  intercellular  adhesion  
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) [6–8]. Adhesion results in 
both the release of eosinophil granule proteins and the generation of signaling events and phenotypic 
changes within the nerve cells [6,9–13]. Released eosinophil granule proteins [6] induce further nerve 
cell signaling and protection from apoptosis [12]. Thus, eosinophils influence nerve function due to 
direct contact via ICAM-1 and VCAM-1 and consequent release of granule proteins. 
S1P and LPA are bioactive phospholipids, which exert many of their effects via G-protein coupled 
S1P  receptors  S1P1,  S1P2,  S1P3,  S1P4  and  S1P5  and  LPA  receptors  LPA1,  LPA2,  LPA3  and  the 
structurally distant LPA4 respectively [14–16] as well as LPA5 which has a distinct expression pattern 
suggesting specific physiological functions [17]. S1P and LPA have both been implicated in various 
aspects  of  neuronal  function  and  activity  and  neuronal  cell  intracellular  signaling,  including 
cytoskeletal reorganization, acetylcoholine release, apoptosis and neurite outgrowth or retraction [18–21]. 
A role for both S1P and LPA and their receptors has also been postulated in airway inflammatory 
responses, for example in allergy (reviewed [22,23]. Both S1P and LPA levels in bronchoalveolar 
lavage  fluid  are  significantly  increased  18-24  h  following  segmental  allergen  challenge  in  allergy 
patients  and  S1P  promotes  airway  remodeling  [24,25].  S1P  is  released  primarily  from  activated 
platelets and activated mast cells [26]. S1P promotes airway remodeling [24] and we and others have 
shown that eosinophils express functional S1P receptors [27,28]. In vitro and animal studies have 
indicated that LPA induces eosinophil and neutrophil migration [29–31]. LPA also induces mast cell 
chemokine  and  histamine  release  [32,33].  Both  S1P  and  LPA  up-regulate  intercellular  adhesion 
molecule-1  (ICAM-1)  in  HUVECs  [34].  Importantly  in  the  context  of  allergy,  S1P  up-regulates 
ICAM-1 in human alveolar epithelial cells [35–37]. 
We  hypothesized  that  cholinergic  nerve  cells  would  express  receptors  for  S1P  and  LPA  and  
that  ligand  binding  to  these  receptors  would  activate  intracellular  signaling  pathways  in  the  nerve  
cells  leading  to  transcriptional  up-regulation  of  ICAM-1  and  of  members  of  the  eosinophil  
eotaxin chemoattractant family. This would further implicate S1P and/or LPA in allergic symptoms  
by  enhancing  eosinophil  accumulation  at  and  adhesion  to  nerve  cells  and  hence  to  nerve  
cell hyperreactivity. Int. J. Mol. Sci. 2011, 12                       
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2. Results and Discussion 
2.1.  IMR32  Cells  Express  S1P1,  S1P3  and  LPA1–3;  S1P  and  LPA  Induce  Up-Regulation  of  
ICAM-1 Transcription 
Given that there is both an increased level and defined source of both LPA and SIP after allergen 
challenge we investigated the role of these lysophospholipids in an in vitro model of eosinophil/nerve 
cell  interactions.  We  and  others  have  used  butyrate-differentiated  IMR-32  cells  as  a  model  of 
cholinergic  nerve  function  in  a  variety  of  studies  [6–11,13,38,39].  They  are  considered  to  be  a 
convenient in vitro model for studying aspects of neurobiology at the molecular and cell level. 
Expression of S1P receptors S1P1 and S1P3 (Figure 1A) and of LPA1–3 (Figure 1B) was confirmed 
in IMR32 cells maintained in proliferation or differentiation medium by real-time PCR. No expression 
of S1P2, S1P4 or S1P5 was detected after 40 cycles of PCR in any cells (Figure 1A); as a positive 
control, expression of all three of these receptors was readily detected on neutrophils (Figure 1A). All 
further experiments were in differentiating IMR32 cells, as these cells display a strongly cholinergic 
phenotype in differentiation medium [8,24,38]. We confirmed by Western blotting that, identically to 
the  cDNA  expression  profile,  differentiating  IMR32  cells  expressed  S1P1,  S1P3  (Figure  1B)  and  
LPA1–3 proteins (Figure 1B), but not S1P2, S1P4 or S1P5. We determined by real time PCR that both 
S1P  (Figure  1C)  and  LPA  (Figure  1C)  increased  expression  of  ICAM-1  two-  to  three-fold  over 
baseline  levels,  a  similar  order  of  magnitude  as  the  positive  control  stimulus,  TNF-  (Figure  1C). 
However, up-regulation of ICAM-1 expression was induced more transiently by LPA (Figure 1C), 
compared to S1P which induced a sustained up-regulation between 30 min to 24 h (Figure 1C), similar 
to TNF- (Figure 1C).  
2.2.  S1P  and  LPA  Induce  ERK  Activation  in  IMR32  Cells  with  Different  Time  Courses  with 
Consequenct Gi-Protein Coupled and ERK-Dependent Up-Regulation of ICAM-1 and/or CCL-26 
To determine the intracellular signaling mechanisms that could mediate S1P- and/or LPA-induced 
up-regulation of ICAM-1 on IMR32 cells, activation of the ERK MAP kinase was examined. Both 
S1P (Figure 2A) and LPA (Figure 2B) induced ERK phosphorylation but with different time courses. 
S1P induced activation of ERK was observable at 30 min of stimulation and remained robust at 1–2 h 
(Figure 2A) while LPA induced a more rapid ERK activation which had fallen to baseline levels 
between  30  and  60  min  of  stimulation  (Figure  2B).  To  further  determine  intracellular  mediators 
involved in S1P- and LPA-induced ICAM-1 up-regulation, IMR32 cells were incubated with S1P 
(1 μM, 2 h) or LPA (1 μM, 30 min). These treatment times were chosen based on the time course for 
ICAM-1 induction (Figure 1C) which suggested that these were the optimal times for S1P and LPA 
respectively. Cells were pre-treated with either the MEK inhibitor PD98059, which prevents ERK 
phosphorylation or with pertussis toxin (PTX), to inhibit the Gi protein, to which all the receptors 
S1P1,  S1P3  and  LPA1–3  can  couple.  S1P-induced  (Figure  2C)  or  LPA-induced  (Figure  2D)  
up-regulation of ICAM-1 was measured by real-time PCR and compared between cells pre-treated 
with PD98059 or PTX and non-pre-treated cells. This revealed that up-regulation of ICAM-1 by both 
S1P and by LPA was dependent on both ERK phosphorylation and on Gi coupling. This is consistent 
with  the  recently  demonstrated  mechanism  of  S1P-induced  up-regulation  of  ICAM-1  in  airway 
epithelial cells [34]. Int. J. Mol. Sci. 2011, 12                       
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Figure 1. S1P and LPA receptors in IMR-32 cells and S1P- or LPA- induced ICAM-1 
transcription.  IMR32 cells were plated in 6-well tissue culture dishes in differentiation 
medium  (5  ×   10
5  per  well)  then  harvested  for:  (A)  RNA  and  cDNA  preparation  and  
semi-quantitative or quantitative PCR using primers for (A) S1P1–5 or LPA1–3 or (B) total 
protein preparation and Western blotting for receptors S1P1, S1P3 or LPA1–3. (C) IMR32 
cells  in  differentiation  medium  were  treated  with:  S1P  (1  μM),  LPA  (1  μM)  or  TNF  
(10 ng/mL) for the indicated times, then harvested for RNA and cDNA preparation and 
real-time PCR using primers for ICAM-1 or β-actin. Results are expressed as fold increase 
in  ICAM-1/β-actin  ratio  over  non-EPO  treated  (0)  cells  (set  to  unity).  Mean  ±   SEM;  
* p < 0.05, **p < 0.01, significantly increased versus untreated cells. 
 
Real-time  PCR  was  also  used  to  monitor  expression  of  the  eosinophil  chemoattractant  CCL26 
(eotaxin-3), normalized to β-actin expression (Figure 2E). Results indicated that at the time points 
shown,  LPA but not S1P up-regulated CCL26 expression (Figure 2E); we have also observed no  
up-regulation  of  CCL26  by  S1P  at  other  time  points  (data  not  shown).  LPA-induced  CCL26  
up-regulation was dependent on ERK phosphorylation and on Gi coupling (Figure 2E). This is the first 
time that LPA but not S1P has been shown to up-regulate expression of an eosinophil chemoattractant, 
CCL26. These results imply that further intracellular mediators are involved in CCL26 expression, 
which are activated by LPA but not S1P, for example the transcription factor STAT-6 [40].  Int. J. Mol. Sci. 2011, 12                       
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Figure  2.  S1P  and  LPA  induce  Gi-mediated  ERK  phosphorylation  and  differential  
up-regulation of ICAM-1 and CCL-26. IMR32 cells in differentiation medium were treated 
with: S1P (A, C, E) (1 μM) or LPA (1 μM) (B, D, E) for the indicated times. Cells were 
harvested  for  cytoplasmic  protein  and  subjected  to  Western  blotting  with  antibody  to 
phosphor-ERK (A, B, top panels) then ERK2 (A, B, bottom panels) for normalization 
Blots shown are representative of three similar experiments. Real-time PCR was carried 
out on cDNA from cells stimulated with S1P or LPA (both 1  μM) in the presence or 
absence of pre-treatment overnight with the MEK/ERK inhibitor PD98059 (50 μM) or the 
Gi protein coupling inhibitor, pertussis toxin (PTX) (0.1 μg/mL) (C, D, E), using primers 
for ICAM-1 (C, D) or CCL-26 (E) or β-actin (C, D, E). Results are expressed as fold 
increase  in ICAM-1/β-actin or CCL-26/β-actin ratio over untreated cells. Mean ±  SEM,  
n = 4; * p < 0.05, LPA-induced fold increase over untreated; 
† p < 0.05, PD98059 or  
PTX-induced reduction in LPA-mediated CCL26 up-regulation. Panel F shows that the 
baseline absolute ratio of ICAM-1 or CCL-26 to β-actin is not significantly different in the 
presence of either inhibitor pre-treatment. 
 Int. J. Mol. Sci. 2011, 12                       
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Figure 3. Eosinophil peroxidase induces ERK-dependent transcriptional up-regulation of 
S1P1 but not S1P3 in IMR32 cells. IMR32 cells in differentiation medium were pre-treated 
or  not  overnight  with  PD98059  (50  μM).  Cells  were  then  treated  with  eosinophil 
peroxidase (EPO) (1 μg/mL) for the indicated times then harvested for RNA and cDNA 
preparation and real-time PCR using primers for: (A) S1P1 or (B) S1P3 or β-actin (A and B). 
Results  are  expressed  as  EPO-induced  fold  increase  in  S1P  receptor/β-actin  ratio  over  
non-EPO treated cells harvested at the same time as the 24 hour time point, which are set to 
unity.  Inserts  show  absolute  values  of  S1P  receptor  versus  β-actin  in  non-EPO-treated 
cells, cultured in the presence or absence of PD98059 pre-treatment, and harvested at the 
same  time  as  the  24  h  time  point  cells.  Mean  ±   SEM;  *  p  <  0.05,  ***  p  <  0.001,  
EPO-induced  fold  increase  in  S1P1  over  untreated; 
†  p  <  0.05, 
†††  p  <  0.001,  
PD98059-induced reduction in EPO-mediated S1P1 up-regulation.  
 
Our previous studies have shown that eosinophils accumulate at cholinergic nerves in human and 
animal models of allergic conditions such as asthma and rhinitis [41]. In vitro, eosinophils adhere to 
primary  nerve  cells  and  to  differentiated  IMR-32  cells  via  the  adhesion  molecules  ICAM-1  and 
VCAM-1, with implications for nerve cell cholinergic phenotype and survival [8–13,38]. In a guinea 
pig model of asthma, accumulation of eosinophils at nerves was significantly decreased by treatment 
with CCR3 antagonist prior to antigen inhalation [5]. CCR3 antagonism also consequently reduced 
antigen-associated  loss  of  M2  receptor  function  [5].  LPA  induced  up-regulation  of  expression  of 
CCL26  message  in  differentiated  IMR-32  cells;  CCL26  (eotaxin-3)  is  a  CCR3  agonist,  which  is  
up-regulated in asthmatics following allergen challenge [42] CCL26 rather than CCL11 (eotaxin-1) or 
CCL24 (eotaxin-2) is therefore suggested to be responsible for continuing eosinophil recruitment at 
later stages following allergen challenge. Furthermore, both S1P and LPA induced up-regulation of 
ICAM-1. Thus S1P and LPA induce conditions whereby eosinophil migration and adhesion to nerve 
cells would be favoured. In the context of allergy, this suggests a previously unrecognized role for 
these  lysophospholipids  in  promotion  of  eosinophil  interaction  with  nerves  and  hence  nerve  cell 
hyperreactivity, with its associated bronchoconstriction.  Int. J. Mol. Sci. 2011, 12                       
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Figure 4. Eosinophil peroxidase induces ERK-dependent transcriptional up-regulation of 
LPA1,  LPA2  and  LPA3  in  IMR32  cells.  IMR32  cells  in  differentiation  medium  were  
pre-treated or not overnight with PD98059 (50 M). Cells were then treated with eosinophil 
peroxidase (EPO) (1 μg/mL) for the indicated times then harvested for RNA and cDNA 
preparation and real-time PCR using primers for: (A) LPA1 or (B) LPA2 or (C) LPA3  
or  β-actin  (A,  B  and  C).  Results  are  expressed  as  EPO-induced  fold  increase  in  LPA  
receptor/β-actin ratio over non-EPO treated cells harvested at the same time as the 24 h  
time point, which are set to unity. Inserts show baseline absolute values of LPA receptor  
versus β-actin in non-EPO treated cells, cultured in the presence or absence of PD98059  
pre-treatment, and harvested at the same time as the 24 hour time point cells. Mean ±  SEM; 
* p < 0.05, *** p < 0.001, EPO-induced fold increase in LPA receptor over untreated;  
† p < 0.05, 
††† p < 0.001, PD98059-induced reduction in EPO-mediated S1P1 up-regulation.  
 
2.3. The Eosinophil Granule Protein EPO Induces Up-Regulation of S1P1, LPA1, LPA2 and LPA3 
Receptors Expression 
We  have  previously  shown  that  eosinophil  adhesion  to  IMR32  cells  induces  eosinophil 
degranulation  and  release  of  granule  proteins,  including  eosinophil  peroxidase  (EPO)  [8–10].  To 
determine whether released eosinophil granule protein could increase expression of IMR32 S1P or 
LPA receptors, nerve cells were treated with eosinophil peroxidase (EPO) (1 μg/mL) for 1, 4, 18 or 24 
h in the presence or absence of PD98059. Real-time PCR was used to monitor the expression of S1P1 Int. J. Mol. Sci. 2011, 12                       
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and  S1P3  receptors  (Figure  3)  or  LPA1,  LPA2  and  LPA3  receptors  (Figure  4).  EPO  significantly 
enhanced expression of S1P1 by approximately 3-4 fold between 4–18 h of stimulation (Figure 3A). 
This up-regulation was dependent on ERK activation as it was abolished in the presence of PD98059. 
S1P3 expression was unaffected by EPO (Figure 3B). LPA1 (Figure 4A), LPA2 (Figure 4B) and LPA3 
(Figure 4C) expression were all raised approximately 3-fold at 18 h of stimulation, then fell back to 
control levels by 24 h. 
These results imply that S1P and LPA, acting via their nerve cell receptors, can promote eosinophil 
recruitment and adhesion and that subsequently, eosinophil adhesion and the resulting degranulation 
can release a factor, namely EPO, which up-regulates the LPA and S1P receptors responsible for this 
effect and hence perpetuate or prolong it.  
In light of the results of our study, it would be of interest to determine whether antagonism of 
individual S1P and/or LPA receptors reduces accumulation at and/or adhesion of eosinophils to nerves 
in animal models of asthma, similarly to CCR3 antagonism. Up-regulation of ICAM-1 by both S1P 
and  LPA  was  dependent  on  Gi-coupling,  as  was  LPA-induced  up-regulation  of  CCL26.  All  the 
receptors IMR-32-expressed receptors, S1P1, S1P3, LPA1, LPA2 and LPA3, couple to Gi. Definitive 
receptor  identification  awaits  further  studies  utilizing  receptor-specific  ligands  or  multiple  siRNA 
technology, which was considered impractical for this work given the abundance of the specific receptors. 
3. Experimental Section 
IMR32 nerve cell culture: The human cholinergic neuroblastoma cell line IMR32 was depleted of 
fibroblasts, as described previously [10]. The cells were maintained in culture in proliferation medium 
(DMEM Plus Glutamax, 5% FCS, 100 U/mL penicillin/streptomycin; GIBCO
® Invitrogen, Paisley, 
UK) at 37 ° C in an atmosphere of 5% CO2. On achieving confluence, cells were plated at a density of  
5 ×  10
5/well in 6-well cell culture dishes and grown in proliferation medium for 48 h. Proliferation 
media  was  then  replaced  by  differentiation  medium  (DMEM  Plus  Glutamax,  2%  FCS,  2  mM  
sodium  butyrate  (Sigma,  Poole,  UK),  100  U/mL  penicillin/streptomycin)  and  cells  were  used  for 
experimentation after  a  further 6  days.  In some  experiments, individual wells were  maintained  in 
proliferation medium in parallel with the differentiating cells. 
mRNA Analysis: Total RNA was isolated from the cells with TRI reagent™ (Sigma),
 according to 
the  manufacturer’s  instructions.  For  both  quantitative  LightCycler
TM  PCRs  (Roche,  Mannheim, 
Germany) and semiquantitative RT-PCRs, 1 μg of RNA was reverse transcribed with AMV reverse 
transcriptase and oligo-dT primer using a 1st strand cDNA synthesis kit (Roche), according to the 
manufacturer’s instructions.  
Semi-quantitative RT-PCR analysis of cDNA preparations was carried out in 50 μL reactions with 
Taq-DNA  polymerase  for  S1P1–5  or  LPA1–3,  using  the  primers  sets  (MWG  Biotech/Eurofins  AG, 
Ebersberg, Germany) outlined in Table 1. PCR conditions were: 94 °C , 4 min (1 cycle); 94 °C , 1.5 min, 
54 °C , 1.5 min, 72 °C , 2 min (25–40 cycles); 72 °C , 10 min (1 cycle). PCR products were separated by 
1.5% agarose gel electrophoresis and photographed under UV illumination. 40 cycles of PCR were 
carried out to verify absence of S1P2, S1P4 and S1P5. 
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Table 1. Primers used in this study. 
Gene  Primer Sequence  Amplicon Length (Base Pairs) 
S1P1  5'-ATCGTCCTGAGCGTCTTCAT-3' (forward) 
5'-CCAGGAAGTACTCCGCTCTG-3' (reverse) 
95 
S1P2  5'-CCAAGCATTATGTGCTGTGC-3' (forward) 
5'-CAGAAGGAGGATGCTGAAGG-3' (reverse) 
186 
S1P3  5'-ACCAGTACGTGGGGAAGTTG-3' (forward) 
5'-GGCAATCAAAACCATCAGGT-3' (reverse) 
105 
S1P4  5'-CCAAGCGCTACATCCTCTTC-3 (forward) 
5'-CAGAGGTTGGAGCCAAAGAC-3' (reverse) 
221 
S1P5  5'-ACAACTACACCGGCAAGCTC-3' (forward) 
5'-GCCCCGACAGTAGGATGTT-3' (reverse) 
218 
LPA1  5'-ATTTCACAGCCCCAGTTCAC-3’ (forward) 
5'-CACCAGCTTGCTGACTGTGT-3' (reverse) 
106 
LPA2  5'-CTGCTCCTGGATGGTTTAGG-3' (forward) 
5'-CTCGGCAAGAGTACACAGCA-3' (reverse) 
95 
LPA3  5'-TTGCCTCTGCAACATCTCTG-3' (forward) 
5'-ATGATGAGGAAGGCCATGAG-3 (reverse) 
82 
ICAM-1  5'-CAAGGCCTCAGTCAGTGTGA-3' (forward) 
5'-CCTCTGGCTTCGTCAGAATC-3' (reverse) 
129 
CCL26  5'-CCTCCTGAGTCTCCACCTTG-3' (forward) 
5'-TGGGAGCAGCTGTTACTGGT-3' (reverse) 
115 
-actin  5'-GGACTTCGAGCAAGAGATGG-3' (forward) 
5'-AGGAAGGAAGGCTGGAAGAG-3' (reverse) 
118 
Quantitative RT-PCR analysis was carried out on the LightCycler
TM (Roche) using fast start Taq 
DNA polymerase containing the double-stranded DNA binding dye SYBR Green 1 as in [38]. Primers 
are shown in Table 1. The samples were denatured
 at 95 °C  for 15 min followed by 35–40 cycles of 
denaturation, annealing and extension
 at 95 °C  for 15 s, 55 °C  for 25 s, and 72 °C  for 11 s (ICAM-1, 
CCL26, S1P1, S1P2, S1P3, S1P4, S1P5, LPA1, LPA2, LPA3), or 95 °C  for 15 s, 55 °C  for 20 s, and 
72 °C  for 20 s (-actin). Characteristic melting
 curves were obtained at the end of amplification by 
cooling the
 samples to 65 °C  for 15 s followed by further cooling to 40 °C
 for 30 s. Serial 10-fold 
dilutions were prepared from individual PCR products, which were then used as standards
 to plot 
against the unknown samples. Quantification of data was
 analyzed using the LightCycler
TM analysis 
software, and values were normalized to the level of β-actin
 expression for each sample on the same 
template cDNA. Results for induction over baseline values of ICAM-1 or CCL26 expression by S1P 
(1 μM) or LPA (1 μM) were obtained; in some experiments fold induction was compared between 
untreated, differentiated IMR32 cells versus cells pre-treated overnight with the MEK/ERK inhibitor 
PD98059 (Sigma) (50 μM) or with pertussis toxin (Sigma) (0.1 μg/mL). Results for induction over 
baseline values of S1P1, S1P3, LPA1, LPA2 or LPA3 by EPO (1 μg /mL, various time points) were also 
compared between untreated, differentiated IMR32 cells versus cells pre-treated overnight with the 
MEK/ERK inhibitor PD98059 (50 μM). 
Nuclear and cytoplasmic protein preparation: IMR-32 cells (5 ×  10
5) were differentiated for 6 days 
with sodium butyrate as described above and then incubated with LPA or S1P for various time periods Int. J. Mol. Sci. 2011, 12                       
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from 2 min to 2 h. Nuclear and cytoplasmic extracts were isolated from IMR-32 cells, essentially as  
in [10]. Protein concentration was established by the Bradford method [43] and nuclear and cytoplasmic 
extracts stored at −80 °C . 
Western blotting: Total cell protein was extracted from IMR32 cells using Tri Reagent, according to 
the  manufacturer’s  instructions  and  quantified  according  to  the  Bradford  method  [43].  Total  cell 
protein  (S1P1–5,  LPA1–3  probing) or  cytoplasmic protein  (ERK probing) (10 μg) was subjected  to 
Western  blotting  as  previously  described  [38]  Membranes  were  incubated  in  blocking  buffer 
(Dulbecco’s PBS (Invitrogen) containing 0.2% (w/v) I-block and 0.1% (v/v) Tween-20) for 1 h at 
room  temperature  then  incubated  for  2  h  in  blocking  buffer  containing  the  individual  respective  
HRP-conjugated primary  antibody  (Santa Cruz, CA,  USA) (1:500 for  each).  Following six 5-min 
washes in washing buffer (PBS pH 7.4, 0.1% (v/v) Tween-20) membranes were incubated for 1 h in 
blocking  buffer  containing  a  dilution  of  the  appropriate  secondary  antibody  (1:10,000  dilution). 
Membranes  were  then  washed  6  times  for  5  min  each  and  exposed  to  SuperSignal  West  Pico 
Chemiluminescent Substrate (Pierce Technology Inc., Rockford, IL, USA) for Western Blotting for 5 min 
at room temperature. Blots were then exposed to X-OMAT light sensitive film to obtain an image.  
Statistical analysis: Values are expressed as mean SEM. The statistical significance of differences 
between  proliferating  and  differentiating  cells  was  evaluated  by  two-tail  Student’s  t-test  or  by 
ANOVA, as appropriate. The Graphpad Instat program was used. A p-value of 0.05 or less was taken 
as significant.  
4. Conclusion 
Eosinophils  accumulate  at  cholinergic  nerves  at  sites  of  inflammation  in  asthma  and  allergic 
rhinitis. We have previously shown that eosinophils adhere to nerve cells via ICAM-1 [6,7]. In this 
study  we  have  shown  that  the  lysophospholipid  LPA  induces  transcriptional  up-regulation  of 
expression of the eosinophil chemoattractant CCL26, which is up-regulated in asthmatics following 
allergen challenge [42] and is suggested to be responsible for continuing eosinophil recruitment at later 
stages  following  allergen  challenge.  Furthermore,  both  LPA  and  another  lysophospholipid,  S1P, 
induce up-regulation of ICAM-1. We and others have previously shown that S1P can also induce a 
direct  chemoattractive  effect  on  eosinophils  [27,28].  Thus  both  S1P  and  LPA  induce  conditions 
whereby eosinophil migration and adhesion to nerve cells would be favored. In the context of allergy, 
this suggests a previously unrecognized role for these lysophospholipids in promotion of eosinophil 
interaction with nerves and hence nerve cell hyperreactivity, with its associated bronchoconstriction. 
Furthermore, the eosinophil granule protein EPO, induced up-regulation of the S1P receptor S1P1 and 
the LPA receptors LPA1-3. We have previously shown EPO to be released from eosinophils upon their 
adhesion to nerve cells via ICAM-1. Hence, the potential exists for a perpetuation of the S1P and LPA 
driven effects on eosinophil and nerve interaction as the EPO released from eosinophils attached to 
nerve cells could cause up-regulation of the S1P and LPA receptors, hence resulting in more S1P and 
LPA binding, more up-regulation of ICAM-1 and CCL-26 and more eosinophil accumulation.  Int. J. Mol. Sci. 2011, 12                       
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